Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC


This is a phase Ib / II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
Abramson, Vandana

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: